Abinav Baweja, MD
Hematology/Oncology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Hospitals listed: John Muir Medical Center - Concord Campus · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Baweja’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A154829 · Current
Licensed to practise in California · since 2018 · expires 2027-05-31 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$269,223
Medicare paid this office $269,223 for 65 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Administration of chemotherapy into vein, 1 hour or less | 18 | $4,460 | $121 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $588 | $29 |
| Injection of additional new drug or substance into vein | 13 | $536 | $16 |
| Insertion of needle into vein for collection of blood sample | 39 | $433 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 38 | $388 | $8 |
See all 7 services
| Administration of chemotherapy into vein, 1 hour or less | 18 | $4,460 | $121 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $588 | $29 |
| Injection of additional new drug or substance into vein | 13 | $536 | $16 |
| Insertion of needle into vein for collection of blood sample | 39 | $433 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 38 | $388 | $8 |
| Blood test, comprehensive group of blood chemicals | 26 | $342 | $10 |
| Injection of drug or substance under skin or into muscle | 16 | $313 | $12 |
Who their Medicare patients are
65 Original Medicare patients in 2024. Average age 78 · Women 49% · Health risk score 2.71. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 72% · Cancer 45% · Chronic kidney disease 37% · Coronary heart disease 31% · Atrial fibrillation 22% · Depression 20% · Heart failure 18% · Stroke 17%.
The office billed $1,104,512, Medicare allowed $340,036 and paid $269,223; for 10,183 services of 76 kinds; $257,380 of it was for drugs given in the office and $11,843 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 65 | 10,183 | 78 | 2.71 | $1,104,512 | $269,223 |
| 2023 | 642 | 113,463 | 77 | 1.96 | $10,422,072 | $2,919,857 |
| 2022 | 272 | 23,600 | 77 | 2.05 | $2,449,926 | $687,983 |
| 2019 | 83 | 89 | 75 | 2.58 | $48,582 | $8,946 |
| 2018 | 81 | 83 | 74 | 3.00 | $49,765 | $9,670 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 41 services
| Long return visit (40+ min) | 295 | $110,922 | $155 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11 | $89,709 | None |
| Injection, denosumab, 1 mg | 23 | $74,366 | None |
| Return visit (30+ min) | 280 | $47,916 | $115 |
| Administration of chemotherapy into vein, 1 hour or less | 60 | $39,075 | $138 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 11 | $27,613 | None |
| New patient visit (60+ min) | 108 | $19,028 | $176 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $17,882 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $16,135 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $14,496 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $13,068 | $154 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $9,395 | $67 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $7,418 | $30 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $6,588 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $6,539 | $105 |
| Insertion of needle into vein for collection of blood sample | 194 | $5,385 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $4,724 | $67 |
| Drawing of blood for a medical problem | 16 | $4,703 | $100 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 184 | $4,463 | $8 |
| Blood test, comprehensive group of blood chemicals | 142 | $4,372 | $10 |
| Injection of additional new drug or substance into vein | 42 | $4,070 | $16 |
| New patient visit (45+ min) | 28 | $3,849 | $137 |
| Administration of chemotherapy into vein, each additional hour | 22 | $3,702 | $29 |
| Short return visit (20+ min) | 35 | $3,595 | $76 |
| Injection of drug or substance under skin or into muscle | 52 | $2,968 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $2,742 | $20 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $1,750 | $34 |
| Irrigation of implanted venous access drug delivery device | 15 | $1,378 | $25 |
| Injection, fosaprepitant, 1 mg | 13 | $1,276 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $1,171 | $43 |
| Ferritin (blood protein) level | 41 | $949 | $13 |
| Injection, palonosetron hcl, 25 mcg | 19 | $887 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $763 | $13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 19 | $685 | $29 |
| Lactate dehydrogenase (enzyme) level | 38 | $633 | $6 |
| Uric acid level, blood | 24 | $337 | $4 |
| Infusion, normal saline solution , 1000 cc | 18 | $219 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $155 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 27 | $123 | None |
| Iron level | 11 | $95 | $6 |
| Infusion, normal saline solution, 250 cc | 19 | $83 | None |
2022: 22 services
| Long return visit (40+ min) | 138 | $33,695 | $165 |
| Return visit (30+ min) | 82 | $11,408 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $10,860 | $90 |
| Administration of chemotherapy into vein, 1 hour or less | 25 | $9,229 | $142 |
| New patient visit (60+ min) | 33 | $6,631 | $201 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,458 | $175 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $5,990 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $2,232 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 18 | $1,577 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,280 | $64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 87 | $1,218 | $8 |
| Blood test, comprehensive group of blood chemicals | 65 | $1,201 | $10 |
| Injection of additional new drug or substance into vein | 17 | $1,106 | $16 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $671 | $34 |
| Injection of drug or substance under skin or into muscle | 19 | $618 | $14 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $526 | $29 |
| Insertion of needle into vein for collection of blood sample | 94 | $497 | $3 |
| Ferritin (blood protein) level | 18 | $307 | $13 |
| Lactate dehydrogenase (enzyme) level | 17 | $124 | $6 |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $67 | None |
| Uric acid level, blood | 11 | $62 | $4 |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $39 | None |
2019: 3 services
| Initial hospital observation care per day, typically 70 minutes | 27 | $4,248 | $157 |
| Emergency department visit with moderate level of medical decision making | 18 | $1,760 | $98 |
| Emergency department visit with low level of medical decision making | 15 | $877 | $52 |
2018: 4 services
| Initial hospital observation care per day, typically 70 minutes | 13 | $2,061 | $159 |
| Emergency department visit with moderate level of medical decision making | 21 | $2,051 | $98 |
| Initial hospital observation care per day, typically 50 minutes | 17 | $1,882 | $111 |
| Emergency department visit with high level of medical decision making | 11 | $1,725 | $144 |
Medicaid work
$735 in 2023
Medicaid paid $735 for 15 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 15 | $735 |
| 2023 | 15 | 1 | 12 | $735 |
| 2022 | 17 | 1 | 16 | $1,097 |
See the largest Medicaid services in earlier years
2022
| Long return visit (40+ min) | 17 | $1,097 |
Drugs they prescribed that Part D paid
$111,656
Pharmacies billed $111,656 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 111) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
77 generic and 34 brand-name prescriptions · $111,656 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 16 | $25,555 | $1,597 |
| Xarelto | 15 | $11,507 | $767 |
Year by year
| 2024 | 111 | 43 | 0% (0) | 31% | $111,656 |
| 2023 | 243 | 76 | None | None | $407,707 |
| 2022 | 47 | 26 | None | 26% | $189,623 |
| 2021 | 11 | None | 0% (0) | None | $3,896 |
| 2018 | 202 | 22 | 0% (0) | 20% | $9,337 |
| 2017 | 260 | 28 | 0% (0) | None | $15,096 |
| 2016 | 383 | 41 | 0% (0) | None | $23,361 |
| 2015 | 65 | 12 | 0% (0) | None | $1,583 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Eliquis | 21 | $23,187 | $1,104 |
| Xarelto | 11 | $13,307 | $1,210 |
| Anastrozole | 12 | $327 | $27 |
| Gabapentin | 14 | $157 | $11 |
| Prednisone | 12 | $102 | $9 |
2018: 7 drugs
| Ventolin Hfa | 13 | $708 | $54 |
| Nifedipine Er | 15 | $181 | $12 |
| Atorvastatin | 16 | $108 | $7 |
| Lisinopril | 20 | $55 | $3 |
| Hydrochlorothiazide | 13 | $47 | $4 |
| Furosemide | 14 | $34 | $2 |
| Carvedilol | 12 | $26 | $2 |
2017: 9 drugs
| Janumet | 16 | $6,186 | $387 |
| Nifedipine Er | 15 | $213 | $14 |
| Atorvastatin | 16 | $184 | $12 |
| Clopidogrel | 11 | $94 | $9 |
| Omeprazole | 21 | $83 | $4 |
| Lisinopril | 22 | $60 | $3 |
| Carvedilol | 15 | $41 | $3 |
| Furosemide | 12 | $29 | $2 |
| Amlodipine Besylate | 12 | $27 | $2 |
2016: 10 drugs
| Nexium | 11 | $2,722 | $247 |
| Metoprolol | 15 | $417 | $28 |
| Atorvastatin | 30 | $372 | $12 |
| Nifedipine Er | 11 | $193 | $18 |
| Clopidogrel | 16 | $168 | $11 |
| Amlodipine Besylate | 27 | $82 | $3 |
| Carvedilol | 23 | $71 | $3 |
| Lisinopril | 24 | $64 | $3 |
| Metformin | 21 | $60 | $3 |
| Furosemide | 22 | $54 | $2 |
Money from drug and device companies
$53 in 2025
| 2025 | 2 | 2 | None | $53 |
| 2024 | 1 | 1 | None | $25 |
| 2023 | 34 | 86 | None | $1,858 |
| 2022 | 12 | 19 | None | $516 |
| 2020 | 1 | 1 | None | $97 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Jemperli | $34 | 1 payment
|
| Alnylam Pharmaceuticals | Givlaari | $19 | 1 payment
|
See all 2 published payments
| GlaxoSmithKline | Meals · 2025-12-11 | Jemperli | $34 |
| Alnylam Pharmaceuticals | Meals · 2025-01-07 | Givlaari | $19 |
See earlier years (2024, 2023, 2022, 2020)
2024: $25
| Novartis Pharmaceuticals | Scemblix | $25 | 1 payment
|
2023: $1,858
| Merck Sharp & Dohme | Keytruda | $159 | 6 payments
|
| Janssen Biotech | Imbruvica | $146 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $127 | 8 payments
|
| Seagen | Tukysa | $119 | 5 payments
|
| Daiichi Sankyo | Injectafer | $112 | 5 payments
|
| Celgene | Pomalyst | $106 | 4 payments
|
| Pfizer | Bosulif | $104 | 5 payments
|
| Genentech USA | Perjeta | $93 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $67 | 3 payments
|
| Taiho Oncology | Lonsurf | $60 | 3 payments
|
| Kite Pharma | Yescarta | $57 | 3 payments
|
| Genzyme | Sarclisa | $55 | 2 payments
|
| Novartis Pharmaceuticals | Scemblix | $53 | 2 payments
|
| Astellas Pharma US | Padcev | $50 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $48 | 2 payments
|
| EMD Serono | Tepmetko | $43 | 2 payments
|
| Alnylam Pharmaceuticals | Givlaari | $38 | 2 payments
|
| Amgen | Lumakras | $37 | 2 payments
|
| Exelixis | Cabometyx | $30 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $30 | 2 payments
|
| Sumitomo Pharma America | Orgovyx | $28 | 1 payment
|
| Octapharma USA | Panzyga | $27 | 1 payment
|
| Gilead Sciences | Trodelvy | $27 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $26 | 1 payment
|
| ImmunoGen | Elahere | $24 | 1 payment
|
| Mirati Therapeutics | Krazati | $24 | 1 payment
|
| Array Biopharma | Braftovi | $24 | 1 payment
|
| Apellis Pharmaceuticals | None | $23 | 1 payment
|
| Foundation Medicine | None | $23 | 1 payment
|
| Genmab U.S. | Epkinly | $22 | 1 payment
|
| Incyte | Jakafi | $22 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $20 | 1 payment
|
| Recordati Rare Diseases Inc. | Sylvant | $18 | 1 payment
|
| Eisai | Lenvima | $15 | 1 payment
|
2022: $516
| Sanofi-Aventis U.S. | Elitek | $82 | 1 payment
|
| Amgen | Lumakras | $76 | 3 payments
|
| Genzyme | Elitek | $67 | 2 payments
|
| Seagen | Padcev | $65 | 2 payments
|
| Celgene | Pomalyst | $46 | 2 payments
|
| Taiho Oncology | Lonsurf | $39 | 2 payments
|
| Janssen Biotech | Erleada | $33 | 1 payment
|
| Daiichi Sankyo | Injectafer | $29 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $21 | 1 payment
|
| Eisai | Lenvima | $21 | 1 payment
|
| Pfizer | Inlyta | $12 | 1 payment
|
2020: $97
| Exelixis | Cabometyx | $97 | 1 payment
|
Checkups this office reported
17 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 85.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 39%That's less than half. | 28 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 80%That's most of the people this applied to. | 419 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 2%That's few of the people this applied to. Better on this measure. | 43 |
| Breast cancer screeningEligible women who got a mammogram | 79%That's most of the people this applied to. | 294 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 60%That's more than half. | 302 |
| Checked for fall riskOlder patients screened for fall risk | 62%That's more than half. | 913 |
| Colon cancer screeningEligible adults who got a colon cancer test | 68%That's more than half. | 674 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 92%That's most of the people this applied to. | 1,115 |
See the other 9 measures
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 31%That's less than half. | 116 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 17%That's few of the people this applied to. Better on this measure. | 116 |
| HIV screeningEligible patients who were screened for HIV | 33%That's less than half. | 640 |
| Medications listed in the chartVisits where the current medication list was documented | 99%That's most of the people this applied to. | 3,502 |
| Oncology: Medical and Radiation - Pain Intensity QuantifiedAs Medicare defines this measure | 98% | 851 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 406 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 100%That's most of the people this applied to. | 82 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 81%That's most of the people this applied to. | 611 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 47%That's less than half. | 1,327 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Improved the patient portal
- Lets patients read their visit notes
- Reports cases to public health electronically
- Reports immunizations to the state registry
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
Professional record
- NPI
- 1770961575
- Licence
- CA A154829California A154829: Current · expires 2027-05-31
- Trained
- University of California, Geffen School of Medicine, 2015
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Hospitalist (208M00000X)
- Mailing address
- 5555 W Las Positas Blvd, Pleasanton, CA, 94588
- NPI first listed
- 2015-05-12
- NPI last updated
- 2025-09-11
- NPI record certified
- 2025-09-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 200 Med Plaza, Los Angeles, CA, 90024 · 550 1st Ave, New York, NY, 10016 · 101 the City Dr S, Orange, CA, 92868 · 400 Taylor Blvd # 200, Pleasant Hill, CA, 94523